GlassScriptPhysician profile
Matthew R Selmon
NPI 1316990922
$5,277.80
in general payments reported to CMS, 2019-2025
33 companies · $561 in 2025
The $561 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $543 · 2021: $841 · 2022: $620 · 2023: $656 · 2024: $733 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,196.86 | 2019-2025 | Repatha, Repatha |
| Abiomed | $492.74 | 2019-2024 | Impella |
| Janssen Pharmaceuticals, INC | $413.15 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $410.06 | 2019-2021 | |
| Boston Scientific Corporation | $332.99 | 2020-2024 | Watchman Access System |
| Abbott Laboratories | $325.28 | 2022-2024 | Ultreon, Jot Dx |
| Acist Medical Systems, INC. | $191.35 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $178.43 | 2021-2024 | |
| Angiodynamics, INC. | $164.93 | 2019-2020 | |
| Penumbra, INC. | $159.87 | 2025 | Penumbra System, Indigo System |
| Medtronic, INC. | $156.31 | 2021-2025 | Ffrangio, Corevalve Evolut R |
| Biotronik INC. | $153.38 | 2019 | |
| Becton, Dickinson and Company | $120.62 | 2024-2025 | Rotarexs 6 F X 135 Cm, Venovo |
| Inari Medical, INC. | $116.34 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Tactile Systems Technology INC | $87.96 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $86.96 | 2023 | Optimizer |
| Shockwave Medical, INC | $86.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $78.51 | 2019 | |
| Medtronic Vascular, INC. | $70.14 | 2019 | |
| Avinger INC. | $62.23 | 2020 | |
| Terumo Medical Corporation | $47.93 | 2022 | |
| Endovascular Engineering INC. | $47.62 | 2024-2025 | Helo Thrombectomy System |
| Regeneron Healthcare Solutions, INC. | $45.44 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $39.07 | 2021-2022 | |
| Philips North America LLC | $38.97 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.19 | 2021 | |
| Novo Nordisk INC | $32.52 | 2025 | Ozempic |
| Chiesi USA, INC. | $28.26 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $24.64 | 2021 | |
| Biocompatibles, INC. | $20.36 | 2019 | |
| Atricure, INC. | $19.85 | 2023 | |
| Cashflow Solutions, LLC | $10.56 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Selmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.